|
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4351-4358.
Prepublished online as a Blood First Edition Paper on August 23, 2005; DOI 10.1182/blood-2005-03-1029.
Previous Article | Table of Contents | Next Article 
PHAGOCYTES
1 ,25-dihydroxyvitamin D3 is a potent suppressor of interferon mediated macrophage activation
Laura Helming,
Jens Böse,
Jan Ehrchen,
Stefanie Schiebe,
Thomas Frahm,
Robert Geffers,
Michael Probst-Kepper,
Rudi Balling, and
Andreas Lengeling
From the Junior Research Group Infection Genetics, German Research Centre for Biotechnology, Braunschweig, Germany; Institute for Experimental Dermatology, University of Münster, Münster, Germany; Department of Gene Regulation and Differentiation, German Research Centre for Biotechnology, Braunschweig, Germany; Research Group Mucosal Immunity, German Research Centre for Biotechnology, Braunschweig, Germany; German Research Centre for Biotechnology, Braunschweig, Germany; and Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
1 ,25-dihydroxyvitamin D3 (1 ,25(OH)2D3), the activated vitamin D3 hormone, is a key regulator of calcium homeostasis and thereby indispensable for bone metabolism. In addition, 1 ,25(OH)2D3 is known to mediate predominantly immunosuppressive responses in vitro and in vivo. It has been demonstrated that macrophages can produce 1 ,25(OH)2D3 on activation with interferon (IFN- ), although little is understood about the biologic significance of this response. We show here that 1 ,25(OH)2D3 can selectively suppress key effector functions of IFN- activated macrophages. Among these are the suppression of listericidal activity, the inhibition of phagocyte oxidase-mediated oxidative burst, and the suppression of important IFN- induced genes, including Ccl5, Cxcl10, Cxcl9, Irf2, Fcgr1, Fcgr3, and Tlr2. The deactivation of IFN- stimulated macrophages is dependent on a functional vitamin D receptor and 1 ,25(OH)2D3 acts specifically on IFN- activated macrophages, whereas the steroid has no effects on resting macrophages. Therefore, the 1 ,25(OH)2D3mediated suppression of macrophage functions is distinct from previously described macrophage deactivation mechanisms. In conclusion, our data indicate that the production of 1 ,25(OH)2D3 by IFN- stimulated macrophages might be an important negative feedback mechanism to control innate and inflammatory responses of activated macrophages.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Bruce, J. P. Whitcomb, A. August, M. A. McDowell, and M. T. Cantorna
Elevated non-specific immunity and normal Listeria clearance in young and old vitamin D receptor knockout mice
Int. Immunol.,
February 1, 2009;
21(2):
113 - 122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Alborzi, N. A. Patel, C. Peterson, J. E. Bills, D. M. Bekele, Z. Bunaye, R. P. Light, and R. Agarwal
Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial
Hypertension,
August 1, 2008;
52(2):
249 - 255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cutolo and K. Otsa
Review: Vitamin D, immunity and lupus
Lupus,
January 1, 2008;
17(1):
6 - 10.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ehrchen, L. Helming, G. Varga, B. Pasche, K. Loser, M. Gunzer, C. Sunderkotter, C. Sorg, J. Roth, and A. Lengeling
Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major
FASEB J,
October 1, 2007;
21(12):
3208 - 3218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Arnson, H. Amital, and Y. Shoenfeld
Vitamin D and autoimmunity: new aetiological and therapeutic considerations
Ann Rheum Dis,
September 1, 2007;
66(9):
1137 - 1142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-H. Choi, R. Bernardi, P. P. Pandolfi, and E. N. Benveniste
The promyelocytic leukemia protein functions as a negative regulator of IFN-{gamma} signaling
PNAS,
December 5, 2006;
103(49):
18715 - 18720.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. McCarty and K. I. Block
Toward a Core Nutraceutical Program for Cancer Management
Integr Cancer Ther,
June 1, 2006;
5(2):
150 - 171.
[Abstract]
[PDF]
|
 |
|
|
|